Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Vir Biotechnology, Inc. (VIR)

9.37   0.16 (1.74%) 09-29 16:00
Open: 9.3 Pre. Close: 9.21
High: 9.49 Low: 9.292
Volume: 1,192,704 Market Cap: 1,258(M)

Technical analysis

as of: 2023-09-29 4:31:07 PM
Short-term rate:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Mid-term rate:       
Target: Six months: 13.54     One year: 15.49
Support: Support1: 8.89    Support2: 7.4
Resistance: Resistance1: 11.6    Resistance2: 13.27
Pivot: 9.64
Moving Average: MA(5): 9.26     MA(20): 10.2
MA(100): 18.41     MA(250): 22.34
MACD: MACD(12,26): -1.1     Signal(9): -1.2
Stochastic oscillator: %K(14,3): 14.9     %D(3): 12.2
RSI: RSI(14): 24.8
52-week: High: 31.54  Low: 8.89
Average Vol(K): 3-Month: 1,601 (K)  10-Days: 1,419 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ VIR ] has closed above bottom band by 35.4%. Bollinger Bands are 56.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 9.5 - 9.54 9.54 - 9.58
Low: 9.18 - 9.23 9.23 - 9.28
Close: 9.29 - 9.37 9.37 - 9.44

Company Description

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Headline News

Thu, 28 Sep 2023
Hepatitis-B-Virus Infection Pipeline and Clinical Trials Pipeline Analysis 2023 (Updated): 80+ Companies - Benzinga

Wed, 27 Sep 2023
2023-09-27 | NDAQ:VIR | Press Release | Vir Biotechnology Inc - Stockhouse Publishing

Wed, 27 Sep 2023
Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by Wedge ... - MarketBeat

Wed, 20 Sep 2023
HIV Vaccine Candidate Expects Early Data in 2024 — Precision ... - Precision Vaccinations

Wed, 20 Sep 2023
Vir Biotechnology Announces First Participant Dosed in New Phase ... - BioSpace

Wed, 06 Sep 2023
Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Acquired by ... - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 134 (M)
Shares Float 89 (M)
% Held by Insiders 14.2 (%)
% Held by Institutions 75.9 (%)
Shares Short 4,570 (K)
Shares Short P.Month 3,540 (K)

Stock Financials

EPS -1.83
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 13.48
Profit Margin (%) -53.4
Operating Margin (%) -55.1
Return on Assets (ttm) -7
Return on Equity (ttm) -14
Qtrly Rev. Growth 0
Gross Profit (p.s.) 7.67
Sales Per Share 3.65
EBITDA (p.s.) -1.91
Qtrly Earnings Growth 0
Operating Cash Flow -362 (M)
Levered Free Cash Flow -365 (M)

Stock Valuations

PE Ratio -5.15
PEG Ratio -0.3
Price to Book value 0.69
Price to Sales 2.56
Price to Cash Flow -3.48

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.